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ABSTRACT 
The fluoroquinolone class of antibiotics have a well-established structure-activity relationship 
(SAR) and a long history in the clinic, but the effect of electron-rich benzofused substituents 
at the N1 position remains poorly explored. Since groups at this position are part of the 
topoisomerase-DNA binding complex and form a hydrophobic interaction with the major 
groove of DNA, it was hypothesised that an electron-rich benzofused N1 substituent could 
enhance this interaction. Molecular modelling techniques were employed to evaluate the 
binding of certain N1-modified fluoroquinolones to DNA gyrase targets from both 
Staphylococcus aureus and Klebsiella pneumoniae species compared with ciprofloxacin and 
norfloxacin. Seven N1-modified fluoroquinolones were subsequently synthesised and tested 
against a panel of Gram-negative pathogens to determine minimum inhibitory concentration 
(MIC) values. Gram-negative outer membrane penetration was investigated using the 
membrane permeabiliser polymyxin B nonapeptide (PMBN) and compound efflux via RND-
family efflux transporters was evaluated using the known efflux pump inhibitor phenylalanine-
arginine beta-naphthylamide (PAβN). Additionally, the target inhibitory activity of 
representative compound 6e was determined in a cell-free environment. A correlation between 
N1 substituent hydrophobicity and activity was observed across the MIC panel, with compound 
activity decreasing with increased hydrophobicity. Those compounds with highest 
hydrophobicity were inactive due to poor solubility profiles whereas compounds with 
intermediate hydrophobicity were inactive due to impaired outer membrane penetration and 
reduced inhibition of topoisomerase targets, the latter in contrast to modelling predictions. This 
study adds new information to the fluoroquinolone SAR and suggests limited utility of large 
hydrophobic substituents at the N1 position of fluoroquinolones. 
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INTRODUCTION 
Drug design is made far more challenging when structural information about the biological 
target in question is lacking or the mechanism of action of a hit compound is unknown. While 
recent advances in the field of protein crystallography have allowed the structures of many 
challenging targets to be solved1, molecular modelling has traditionally been employed in such 
cases to allow the rational design and improvement of promising drug scaffolds2. Such 
modelling originally took the form of ligand-based quantitative structure-activity relationship 
(QSAR) calculations, used to more effectively rank analogue compounds and optimise 
scaffolds without offering any specific target information, and now includes target-based 
molecular docking for which there are various commercially available software suites. Through 
this, molecular modelling has become a companion technique to traditional compound 
screening efforts, allowing cheaper and quicker evaluation of chemical libraries against 
specified targets2. The caveat, of course, is that such data is only as useful as the model is 
accurate. While full quantum mechanical simulations would likely provide the highest degree 
of accuracy, the extreme computational burden involved in realising such a model on the 
protein scale continues to make this approach untenable. Instead, modelling suites employ 
coarse grain molecular dynamics simulations for the majority of the biological target, the more 
resource-intensive quantum mechanical simulations reserved for small, specific areas with 
which the drug is likely to directly interact3. This compromise inevitably limits the utility of 
the data generated, the result being that drug discovery efforts are still primarily driven by in 
vitro and in vivo assays. Despite this, we opine that the refinement of older, successful drug 
scaffolds developed in the pre-modelling era represents a task to which current modelling suites 
are well suited. 
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One such scaffold is that of the fluoroquinolones. The fluoroquinolones are a family of 
synthetic, broad-spectrum antibiotic compounds and are important antimicrobial tools within 
the modern medical arsenal. They remain one of the most frequently prescribed families of 
antibiotics globally4 with a combined 17% share of the $43.9bn global antibiotics market in 
2014, second only to the β-lactams5. Since the discovery of nalidixic acid by Lesher and co-
workers in 19626, several generations of fluoroquinolone antibiotics have reached the market 
including ciprofloxacin, levofloxacin and moxifloxacin (Figure 1)7-8. However, the class is not 
without its controversy. The FDA added black box warnings to fluoroquinolone-class drugs in 
2008 in response to evidence of increased risk of tendon damage9 and a number of FDA 
approved fluoroquinolones including temafloxacin, grepafloxacin and trovafloxacin have 
either been withdrawn from the clinic or suffered heavily restricted use due to severe adverse 
effects10. Despite further warnings by the FDA in 2013 and then 201611, the increasing threat 
posed by antimicrobial resistance worldwide has stimulated renewed interest in the 
fluoroquinolones. In June 2017, the FDA approved Melinta Therapeutics’ delafloxacin12; other 
quinolones currently in clinical trials include lascufloxacin (Kyorin Pharmaceutical Co. Ltd.), 
finafloxacin (MerLion Pharmaceuticals Pte Ltd.), nemonoxacin (TaiGen Biotechnology Co. 
Ltd.), OPS-2071 (Otsuka Pharmaceutical Co. Ltd.) and levonadifloxacin (Wockhardt Ltd.)13.  
 
 
Figure 1. Different generations of quinolone family antibiotics. The second generation of quinolones 
were the first to feature fluorine atoms at the C6 position, hence the adoption of the fluoro- prefix for 
subsequent compounds. 
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Fluoroquinolones inhibit the actions of DNA gyrase and topoisomerase IV, enzymes that 
facilitate local introduction or relaxation of DNA supercoils in order to avoid the occurrence 
of double stranded DNA breaks in the bacterial genome. If the frequency of breaks is high 
enough to overwhelm cellular DNA repair pathways, cell death occurs14-18. To this end, the 
structure-activity relationship of the quinolone core has been studied in detail to determine 
substituents that allow for a broad-spectrum activity profile. Groups at the N1 position are part 
of the topoisomerase-DNA binding complex and form a hydrophobic interaction with the major 
groove of DNA19. A variety of different substituents have found success here, including the 
cyclopropyl ring present in ciprofloxacin and moxifloxacin (traditionally regarded as the 
optimal substituent here for potency20) and the 3,5-difluoropyridin-2-amine group in the newer 
delafloxacin, but the effect of large hydrophobic N1 substituents has yet to be fully explored. 
 
We sought to use a molecular modelling-driven approach to investigate the merit of benzofused 
substituents at the N1 position of the fluoroquinolone nucleus. It was hypothesised that such 
substituents could present a novel means of enhancing the fluoroquinolone-DNA interaction to 
improve upon the levels of activity observed in existing fluoroquinolones. To investigate this 
hypothesis, representative N1-benzofused fluoroquinolones were first docked in silico against 
the DNA gyrase enzymes from Staphylococcus aureus and Klebsiella pneumoniae, then 
synthesised using solution phase chemistry and evaluated in vitro against panels of clinically 
relevant Gram-negative pathogens. 
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RESULTS AND DISCUSSION 
In Silico Modelling. Four novel N1-benzofused fluoroquinolones (6d-g) were modelled 
against the S. aureus and K. pneumoniae DNA gyrase enzymes. Ciprofloxacin (6a), 
norfloxacin (6b) and an N1-benzyl analogue (6c) were included as control compounds. The ten 
most favourable binding poses for each of the seven compounds were selected and compared 
according to both ChemScore and energy of binding. N1-benzofused compounds were all 
predicted to possess enhanced binding energy for both gyrase enzymes (best poses ≥ -25.37 
kcal/mol versus subunit I) compared to norfloxacin (best poses ≤ -21.54 kcal/mol) and 
ciprofloxacin (best poses ≤ -23.59 kcal/mol), especially the benzothiophene-containing 
compounds 6e (best poses ≥ -27.76 kcal/mol) and 6g (best poses ≥ -27.20 kcal/mol) (Table S1). 
Additionally, visual examination of the binding poses predicted for each compound indicated 
the N1-benzofused compounds would bind K. pneumoniae DNA gyrase in a similar manner to 
ciprofloxacin (Figure 2), though this did not appear to be the case with S. aureus (Figure S1). 
To test these predictions, all seven compounds were synthesised for microbiological evaluation 
(Scheme 1).
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Figure 2. (A,B) Molecular modelling results indicate that N1-benzofused compounds (represented by compounds 6e and 6g) bind to K. pneumoniae DNA 
gyrase in a similar manner to compound 6a (ciprofloxacin). Binding poses shown in 2D (A) and 3D (B) views.
A. 
B. 
6a 6e 6g 
8 
 
Results 
Chemistry. Compounds 6a-g were synthesised using an established solution phase route 
(Scheme 1) and characterised using LC-MS, HRMS, IR, 1H and 13C NMR techniques. 
Hydrochloride salt forms were used to improve aqueous solubility for microbiological testing. 
clogP values were calculated for each compound (Table 1). 
 
 
Scheme 1. Synthetic scheme used for the preparation of fluoroquinolones including novel N1-
benzofused analogues. i) (EtO)3CH, Ac2O, 140oC, 3hrs. ii) R-NH2, DCM, rt, 15hrs. iii) DBU, LiCl, 
DCM, 45oC – rt, 17.5hrs. iv) HCl, AcOH, reflux, 2.5hrs. v) Boc-piperazine, K2CO3, DMF, reflux, 15hrs. 
vi) TFA, dry DCM, rt, 2hrs. vii) 4M HCl in dioxane, DCM, rt, 1hr. The seven fluoroquinolone 
compounds synthesised as part of this study were three control compounds (ciprofloxacin, norfloxacin 
and an N-benzyl analogue; 6a-c) and four novel N1-benzofused analogues (6d-g). 
 
Biological Evaluation. The antibacterial activities of the synthesised fluoroquinolones were 
evaluated against a panel of Gram-negative pathogens including Klebsiella pneumoniae 
(NCTC 13368, M6), Acinetobacter baumannii (AYE, ATCC 17978), Pseudomonas 
aeruginosa (PAO1, NCTC 13437) and Escherichia coli (NCTC 12923, LEC001). The ability 
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of molecules to permeate the Gram-negative outer membrane was investigated by adding 
membrane permeabiliser polymyxin B nonapeptide (PMBN) at sub-inhibitory concentrations 
(Table 2). Phenylalanine-arginine beta-naphthylamide (PAβN) was used to investigate 
compound efflux by RND-family efflux pumps (Table 3).
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Table 1. clogP values for compounds 6a-g. Values were calculated using ChemDraw Professional 17.1 and ALOGPS 2.1 software21, respectively. Refer to 
Scheme 1 for full structural details. 
 
 Compound Code 6a 6b 6c 6d 6e 6f 6g 
 
R 
  
     
clogP Calculation Software 
ChemDraw Professional 17.1 -0.73 -0.78 1.25 0.42 0.89 1.81 2.28 
ALOGPS 2.1 -0.57 -0.47 0.41 0.75 1.17 0.89 1.33 
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Table 2. MIC values (mg/L) of synthesised fluoroquinolones. S/R refers to strains susceptibility to ciprofloxacin as defined by the EUCAST clinical 
breakpoints: S indicates a strain is ciprofloxacin-sensitive, while R indicates a strain is ciprofloxacin-resistant. 
 
 
 Compound Code 6a; ciprofloxacin 6b; norfloxacin  6c 6d 6e 6f 6g 
Species Strain S/R -PMBN +PMBN -PMBN +PMBN -PMBN +PMBN -PMBN +PMBN -PMBN +PMBN -PMBN +PMBN -PMBN +PMBN 
K. pneumoniae 
M6 S 0.125 0.125 0.25-0.5 0.5 1 1 1-2 0.5 8 2 >128 >128 >128 >128 
NCTC 13368 R 1 0.5 4 2 16 4 16 2 32 8 >128 >128 >128 >128 
A. baumannii 
ATCC 17978 S 0.5 0.5 8 4 4-8 4 2 1 8 4 >128 >128 >128 >128 
AYE R >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 >128 >128 >128 >128 
P. aeruginosa 
PAO1 S 0.5-2 0.125 2-4 0.5 8 0.5 8-16 0.5 32 2 >128 16 >128 32 
NCTC 13437 R >32 16 >32 32 >32 32 >32 32 >32 32 >128 32 >128 16 
E. coli 
NCTC 12923 S ≤0.03 0.03-0.06 0.125 0.125 1-2 0.5 1 0.25 4 1 >128 32 >128 128 
LEC001 R 16 32 >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 
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Table 3. MIC values (mg/L) of synthesised fluoroquinolone (6e) vs. ciprofloxacin (6a) in the 
presence or absence of the efflux pump inhibitor PAβN. S/R refers to strains susceptibility to 
ciprofloxacin as defined by the EUCAST clinical breakpoints: S indicates a strain is ciprofloxacin-
sensitive, while R indicates a strain is ciprofloxacin-resistant.
 Compound Code 6e 6a; ciprofloxacin 
Species Strain S/R -PAβN +PAβN -PAβN +PAβN 
K. pneumoniae 
M6 S 8 1 ≤0.125 ≤0.125 
NCTC 13368 R >32 4 0.25 0.25 
A. baumannii 
ATCC 17978 S 4 4 ≤0.125 ≤0.125 - 0.5 
AYE R >32 >32 32 >32 
P. aeruginosa 
PAO1 S 32 2 ≤0.125 ≤0.125 
NCTC 13437 R >32 >32 32 16 
E. coli 
NCTC 12923 S 0.25-2 0.25 ≤0.125 ≤0.125 
LEC001 R >32 >32 16 32 
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Across the panel, activity is broadly reduced or abolished in the N1-benzofused analogues 
compared to ciprofloxacin (6a) and norfloxacin (6b); MICs against ciprofloxacin-sensitive 
strains are all ≥4x higher than for ciprofloxacin. The uniformly poor activities of the most 
hydrophobic compounds 6f and 6g are likely a result of their poor solubility profiles. 
 
Klebsiella pneumoniae. For the ciprofloxacin-resistant strain NCTC 13368, PMBN rescues 
the activities of compounds 6d and 6e by 4-8-fold compared to the 2-fold difference seen for 
both norfloxacin and ciprofloxacin. This pattern extends to the ciprofloxacin-sensitive strain 
M6 (2-4-fold versus 1-fold potentiation). Using compound 6e as a reference compound, these 
strains also show significant potentiation with the RND-family efflux inhibitor PAβN, 
suggesting that the compounds are susceptible to efflux. This was not evident for ciprofloxacin. 
 
Acinetobacter baumannii. The trend observed in both K. pneumoniae strains extends to the 
ciprofloxacin-sensitive A. baumannii strain ATCC 17978, with 6d and 6e potentiated 2-fold by 
PMBN versus 1-2-fold for ciprofloxacin and norfloxacin. The ciprofloxacin-resistant strain 
AYE remains highly resistant to all compounds tested, likely due to mutations in gyrA. Neither 
ciprofloxacin nor compound 6e showed any difference in MIC when treated in the presence of 
PAβN. 
 
Pseudomonas aeruginosa. The aforementioned trend is also visible in ciprofloxacin sensitive 
P. aeruginosa strain PAO1, with PMBN potentiating 6d and 6e 16->32-fold versus 4-16-fold 
for norfloxacin and ciprofloxacin. Unlike for both K. pneumoniae and A. baumannii, the 
activities of 6f and 6g were also rescued by over 8-fold against both strains, though all MICs 
remain well above the EUCAST clinical breakpoint for ciprofloxacin. PAO1, but not NCTC 
13437, showed significant potentiation with PAβN. 
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Escherichia coli. PMBN rescues the activity of all analogues by 2->8 fold versus 1->4-fold for 
norfloxacin and ciprofloxacin. No effect was observed with PAβN for either compound 6e or 
ciprofloxacin. 
 
In vitro activity assays using purified S. aureus, E. coli and P. aeruginosa DNA gyrase and S. 
aureus topoisomerase IV enzymes were performed in order to evaluate whether the gains in 
inhibitory activity predicted for the benzofused compounds were accurate. The 
benzothiophene-containing 6e was selected as a representative compound for the purposes of 
this experiment. Results indicate that 6e has a markedly reduced inhibitory activity for the E. 
coli and P. aeruginosa enzymes (6e IC50 = 2.70 µg/mL ± 0.42 and 6.68 µg/mL ± 1.46, 
respectively) compared to ciprofloxacin (IC50 = 0.069 µg/mL ± 0.01 and 0.11 µg/mL ± 0.01, 
respectively) (Figure 3). An accurate IC50 could not be determined for compound 6e against 
the S. aureus DNA gyrase or topoisomerase IV enzymes because the compound was poorly 
soluble in the assay media at the high concentrations required. 
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Figure 3. IC50 analysis for 6e against A) E. coli DNA gyrase and B) P. aeruginosa DNA gyrase.  
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Discussion. A general correlation between N1 substituent hydrophobicity and activity is 
observed; compounds 6c, 6d and 6e are of intermediate hydrophobicity and display limited 
activity, whereas the more hydrophobic 6f and 6g show almost complete loss of activity versus 
ciprofloxacin. Compounds 6d and 6e are less active in K. pneumoniae, P. aeruginosa and E. 
coli due to impaired outer membrane penetration, as evidenced by greater potentiation by 
PMBN versus ciprofloxacin and norfloxacin, lower inhibitory activity for DNA gyrase, as 
indicated by the E. coli and P. aeruginosa IC50s of 6e, and – in the case of P. aeruginosa PAO1 
and both K. pneumoniae strains – efflux by RND-family efflux pumps, as evidenced by 
conducting MICs for 6e with and without the efflux pump inhibitor PAβN. The outer 
membrane of A. baumannii strain ATCC 17978 does not seem to impede compound influx in 
the same way as described above and we can conclude that higher MIC values in the 
benzofused compounds in this strain are solely due to lower inhibitory activity. The uniformly 
poor activities of the most hydrophobic compounds 6f and 6g indicate that these analogues are 
chiefly affected by poor solubility profiles, as was evidenced when undertaking the MIC 
experiments. None of the N1-benzofused analogues showed superior activity to ciprofloxacin 
in ciprofloxacin-resistant strains, indicating that the resistance mechanisms that afflict 
ciprofloxacin in these bacteria are no less effective against the benzofused analogues. 
 
Comparison of the molecular modelling and in vitro data highlights several important points. 
The weakness of any molecular model lies in the variables excluded from it; since whole-cell 
systems are far too large and complex to model currently, the lack of a membrane component 
to simulate compound influx remains a key shortcoming in antibacterial docking efforts. 
However, this does not mean that the predicted gains in gyrase inhibition are incorrect. For 
compounds 6d and 6e which were capable of influx into certain strains of bacteria, the problem 
may be that the ChemScore and binding energy parameters used in the docking are poorly 
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suited to determining whether a fluoroquinolone will inhibit the topoisomerase target. While 
both parameters offer a guide to the most preferable binding pose of a drug by assessing a 
plethora of non-covalent binding interactions, neither considers the individual importance of 
said interactions beyond their relative contributions to likely binding energy. Specifically, 
fluoroquinolones inhibit topoisomerase enzymes by forming a C3 carboxylate magnesium-
water bridge with aspartic/glutamic acid and serine residues in the GyrA/ParC enzyme 
subunits. Therefore, it is plausible that N1-benzofused analogues 6d and 6e do possess higher 
binding energies for the enzyme but show reduced inhibition of it due to an altered binding 
pose. We recommend that this possibility be considered in all future modelling efforts with 
novel fluoroquinolones. This study illustrates that while molecular modelling is a useful 
technique in drug design, it cannot yet be a full substitute for traditional in vitro and in vivo 
compound screening efforts. 
 
MATERIALS AND METHODS 
Synthetic Organic Chemistry 
General. Synthetic building blocks and reagents were purchased from a number of suppliers 
including Fluorochem (UK), Sigma-Aldrich (Merck KGaA, USA), Thermo Fisher Scientific 
(UK, including Acros Organics, Maybridge and Alfa Aesar), Activate Scientific (UK), 
Enamine (Ukraine), VWR International (USA), Oxchem (USA) and Apollo Scientific (UK). 
Solvents were purchased from Sigma-Aldrich and Thermo Fisher Scientific. Thin-layer 
chromatography (TLC) analysis was performed using silica gel plates (Merck silica gel 60 
F254 plates) and visualised using ultraviolet (UV) light (254 nm wavelength) and/or staining 
with potassium permanganate solution. Manual flash column chromatography was performed 
using silica gel (Merck 9385, 230-400 mesh ASTM, 40-63 µM) as the stationary phase. TLC 
was employed to discern solvent systems (mobile phases) with appropriate separation profiles; 
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said profiles were comprised of hexanes and ethyl acetate. Liquid chromatography–mass 
spectrometry (LC-MS) was employed to monitor reaction progression and compound 
identification. LC-MS analysis was performed on a Waters Alliance 2695 HPLC coupled to a 
Waters Micromass ZQ instrument with a Waters 2996 PDA. For liquid chromatography, an 
Onyx™ Monolithic C18 column (50 x 4.6 mm) was used and the mobile phases were 
comprised of water (A) and acetonitrile (B). Formic acid (0.1%) was added to both to ensure 
acidic conditions throughout the analysis. Gradient conditions used were as follows. Method 
A (5 min): from 95% A/5% B to 90% B over 3 min. Then from 90% B to 95% B over 0.5 min 
and held constant for 1 min. This was then reduced to 5% B over 0.5 min. The flow rate was 
1.0 mL/min, 100 μL was split via a zero dead volume T piece which passed into the mass 
spectrometer. The wavelength range of the UV detector was 220-500 nm. Method B (10 min): 
from 95% A/5% B to 50% B over 3 min. Then from 50% B to 80% B over 2 min. Then from 
80% B to 95% B over 1.5 min and held constant for 1.5 min. This was then reduced to 5% B 
over 0.2 min and maintained to 5% B for 1.8 min. The flow rate was 0.5 mL/min, 200 μL was 
split via a zero dead volume T piece which passed into the mass spectrometer. The wavelength 
range of the UV detector was 220-400 nm. Mass spectrometry data (both ESI+ and ESI- modes) 
were collected using the following Waters Micromass ZQ parameters: capillary (kV), 3.38; 
cone (V), 35; extractor (V), 3.0; source temperature (°C), 100; de-solvation temperature (°C), 
200; cone flow rate (L/h), 50; de-solvation flow rate (L/h), 250. High resolution mass spectra 
were obtained on a Thermo Navigator mass spectrometer coupled with liquid chromatography 
(LC) using electrospray ionisation (ES) and time-of-flight (TOF) mass spectrometry. Infrared 
spectra (IR) were recorded on a Perkin Elmer spectrum 1000 instrument. All NMR spectra 
were obtained at room temperature using a Bruker Ascend 400 MHz NMR spectrometer and 
interpreted using ACD/NMR Processor Academic Edition software. Chemical shifts (δ H) are 
expressed in parts per million (ppm) relative to deuterated chloroform (CDCl3, residual signal 
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1H δ = 7.26, 13C δ = 77.2), deuterated dimethyl sulfoxide ((CD3)2SO, residual signal 1H δ = 
2.54, 13C δ = 40.5) or deuterated trifluoroacetic acid (CF3CO2D, residual signal 1H δ = 11.50, 
13C δ = 164.4, 116.5). Coupling constants are expressed in Hz. Multiplicities in 1H NMR 
spectra are quoted as s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet 
of doublets, ddd = doublet of doublet of doublets, dt = doublet of triplets, td = triplet of 
doublets, spt = septet and br = broad. 
 
Microbiological Evaluation 
Minimal Inhibitory Concentrations (MICs). Minimal inhibitory concentrations (MICs) were 
determined using the microdilution broth method. Briefly, compounds were added to the first 
two columns of a 96-well plate and diluted two-fold down the plate in tryptic soy broth (TSB). 
Overnight cultures of bacteria were then adjusted to a concentration of 1x106 CFU/mL and 
added to each well for a final concentration of 5x105 CFU/mL. The MIC was defined as the 
lowest concentration of compound which resulted in no visible growth at an optical density of 
600 nm after 20 hours incubation at 37oC. Where necessary, MIC determinations were carried 
out in the presence of the membrane permeabiliser polymyxin B nonapeptide (PMBN) at a 
final concentration of 30 µg/mL, or an efflux pump inhibitor, PAβN, at a final concentration 
of 25 µg/mL, concentrations which did not affect bacterial growth. 
 
Gyrase Inhibition Assay. DNA gyrase from S. aureus and E. coli were treated with compound 
6e and the positive control ciprofloxacin using the cell-free S. aureus, E. coli and P. aeruginosa 
gyrase supercoiling kits (#SAS4001, K0001, PAS001), and the S. aureus topoisomerase IV 
relaxation kit (SAR4001), all obtained from Inspiralis (Norwich, UK), according to 
manufacturer’s instructions, as described previously22-23. 
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Molecular Modelling 
Generation of Structures. PDB ID code 2XCT was used for the 3D structure of Staphylococcus 
aureus GyrA. The structure of Klebsiella pneumoniae GyrA was generated by homology 
modelling using the FASTA UniProt code A0A0C7K6P2. The sequence identity between the 
target and template protein with PDB ID code 4TMA was 96.57% for K. pneumoniae GyrA. 
The final structures of the gyrase and associated DNA structures were amended and assembled 
using Accelrys Discovery Studio. The 3D structures of ligands were generated using Chem3D 
15.0 software and the structures were minimised with SYBYL. 
 
Molecular Docking. Molecular docking was performed to generate several distinct binding 
orientations and the binding affinity for each binding mode. Subsequently the binding modes 
that showed the highest score and lowest binding energy were considered as the most 
favourable binding modes. AutoDock SMINA was used for blind molecular docking of the 
ligands to gyrase enzymes to find the best binding pocket by exploring all probable binding 
cavities in the enzymes. All parameters were kept at their default values for running SMINA. 
GOLD was then used for molecular docking of the compounds into the SMINA-located 
binding site for performing flexible molecular docking and determining more precise energies 
and scores. Based on fitness function score and ligand binding position, the best-docked pose 
for each compound was selected; high fitness function scores (generated using GOLD) and low 
binding energy values are indicative of the best-docked pose for each system. A genetic 
algorithm (GA) is used in GOLD ligand docking to thoroughly examine the ligand 
conformational flexibility along with the partial flexibility of the protein. The maximum 
number of runs was set to 20 for each compound, and the default parameters were selected 
(100 population size, 5 for the number of islands, 100,000 number of operations and 2 for the 
niche size). Default cutoff values of 2.5 Å (dH-X) for hydrogen bonds and 4.0 Å for van-der-
20 
 
Waals distance were employed. When the top solutions attained the RMSD values within 1.5 
A˚, the GA docking was terminated. 
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CONCLUSION 
This study suggests large hydrophobic groups, particularly aromatic benzofused rings, have 
limited utility at the N1 position of fluoroquinolones as they significantly alter the 
physicochemical and drug-like properties of the molecules. Electron-rich, hydrophobic, 
benzofused substitutions negatively impact penetration of the Gram-negative outer membrane 
in K. pneumoniae, P. aeruginosa and E. coli and do not afford protection from existing 
fluoroquinolone resistance mechanisms present in these species. These modifications also 
reduce target inhibition (other factors, including substituent size and geometry, are clearly 
intrinsic determinants of biological activity) and compound solubility in aqueous media. 
However, the modifications considered herein may not represent the full potential of such 
modifications; more highly functionalised, polar heteroaromatic groups may yet prove 
promising N1 substituents for the next generation of fluoroquinolones. The findings also 
suggest that, while still a powerful technique, molecular modelling alone was unable to 
successfully predict improvements to the fluoroquinolone scaffold at the N1 position, both due 
to considerations outside of the scope of the model (membrane penetration, compound 
solubility) and inaccuracies inherent to current modelling techniques (poor prediction of 
compound affinity for target with regards to inhibition).   
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EXPERIMENTAL SECTION 
General Procedure for Compounds 2a – g. Ethyl 2,4,5-trifluorobenzoylacetate (1; 1 g, 4.06 
mmol, 1 eq.) was dissolved in triethyl orthoformate (1.15 mL, 6.90 mmol, 1.7 eq.) and heated 
at 140 °C for 30 minutes. Acetic anhydride (1.15 mL, 12.19 mmol, 3 eq.) was added and the 
mixture refluxed at 140 °C for another 3 hours. Upon completion, the reaction was cooled to 
room temperature, DCM (3 mL) was added and the mixture was stirred at room temperature 
for 10 minutes. Then cyclopropylamine (703 μL, 10.15 mmol, 2.5 eq.) was added and the 
reaction was stirred at room temperature until completion. The crude was concentrated in vacuo 
and the resulting solid was dissolved in DCM (2 mL) and purified by flash chromatography 
(50% Hex/50% EtOAc) to yield compound 2a, pale yellow solid, 1.158 g (91.0% yield); 1H 
NMR (400 MHz, CDCl3) δ 10.87 (d, J = 12.59 Hz, 0.75H, H4), 9.42 (d, J = 13.60 Hz, 0.25H, 
H4), 8.20 (d, J = 13.85 Hz, 0.75H, H3), 8.16 (d, J = 14.35 Hz, 0.25H, H3), 7.33 (ddd, J = 10.07, 
8.81, 6.29 Hz, 0.25H, H1), 7.19 (ddd, J = 9.82, 8.81, 6.29 Hz, 0.75H, H1), 6.83 - 6.91 (m, 1H, 
H2), 4.05 (q, J = 7.13 Hz, 1.5H, H8), 4.00 (q, J = 7.05 Hz, 0.5H, H8), 2.92 - 3.02 (m, 1H, H5), 
1.08 (t, J = 7.18 Hz, 2.25H, H9), 0.77 - 0.97 (m, 4.75H, H6+7+9); 13C NMR (101 MHz, CDCl3) 
δ 188.1, 186.0, 168.4, 166.6, 160.8, 160.4, 154.1 (ddd, 247.22, 9.54, 2.94 Hz), 150.5 (ddd, 
253.09, 14.67, 12.47 Hz), 146.6 (ddd, 245.02, 12.47, 3.67 Hz), 127.2 - 127.6 (m), 117.7 (ddd, 
J = 20.54, 5.13, 1.47 Hz), 116.8 (ddd, J = 20.54, 5.13, 1.47 Hz), 105.1 (dd, J = 28.61, 21.27 
Hz), 104.9 (dd, J = 28.61, 21.27 Hz), 101.6, 101.6, 59.9, 59.6, 30.4, 30.1, 14.0, 13.6, 6.6, 6.5; 
(max/cm-1) 1686, 1623, 1569, 1508, 1426, 1406, 1357, 1330, 1294, 1244, 1228, 1174, 1136, 
1088, 1058, 1033, 1015, 890, 877, 809, 797, 773, 754, 734, 660, 588. See note A. 
Compound 2b, pale yellow solid, 4.916 g (80.3% yield); 1H NMR (400 MHz, CDCl3) 
δ 10.89 (br. s., 0.8H, H4), 9.40 (br. s., 0.2H, H4), 8.12 (d, J = 14.10 Hz, 0.8H, H3), 8.10 (d, J 
= 14.60 Hz, 0.2H, H3), 7.32 (ddd, J = 9.82, 8.81, 6.29 Hz, 0.2H, H1), 7.19 (ddd, J = 9.82, 8.81, 
6.29 Hz, 0.8H, H1), 6.81 - 6.92 (m, 1H, H2), 4.05 (q, J = 7.18 Hz, 1.6H, H7), 4.00 (q, J = 7.18 
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Hz, 0.4H, H7), 3.44 - 3.55 (m, 2H, H5), 1.36 (t, J = 7.30 Hz, 2.4H, H6), 1.33 (t, J = 7.30 Hz, 
0.6H, H6), 1.07 (t, J = 7.18 Hz, 2.4H, H8), 0.94 (t, J = 7.18 Hz, 0.6H, H8); 13C NMR (101 
MHz, CDCl3) δ 188.0, 168.6 (d, J = 1.47 Hz), 166.8 (d, J = 1.47 Hz), 160.2, 160.0, 159.8, 154.1 
(ddd, J = 247.22, 9.54, 2.20 Hz), 150.4 (ddd, J = 253.09, 14.67, 12.47 Hz), 146.6 (ddd, J = 
245.02, 13.20, 3.67 Hz), 127.4 - 127.7 (m), 116.7 (ddd, J = 20.54, 5.87, 1.47 Hz), 105.0 (dd, J 
= 28.61, 20.54 Hz), 101.0, 100.8, 59.8, 59.5, 45.1, 44.9, 44.8, 15.8, 15.7, 15.7, 14.0, 13.6; 
(max/cm-1) 1678, 1622, 1560, 1510, 1428, 1415, 1380, 1364, 1330, 1310, 1283, 1244, 1219, 
1175, 1156, 1136, 1092, 1050, 1036, 884, 1015, 863, 829, 800, 774. See note A. 
Compound 2c, pale yellow solid, 1.039 g (70.7% yield); 1H NMR (400 MHz, CDCl3) 
δ 11.10 (br. s., 0.75H), 9.63 (br. s., 0.25H), 8.14 - 8.23 (m, 1H), 7.34 - 7.45 (m, 3H), 7.27 - 7.33 
(m, 2H), 7.21 (ddd, J = 10.01, 8.75, 6.17 Hz, 1H), 6.83 - 6.92 (m, 1H), 4.58 - 4.64 (m, 2H), 
4.06 (q, J = 7.05 Hz, 1.5H), 4.01 (q, J = 7.05 Hz, 0.5H), 1.08 (t, J = 7.05 Hz, 2.25H), 0.95 (t, J 
= 7.05 Hz, 0.75H); 13C NMR (101 MHz, CDCl3) δ 188.3, 166.7, 160.4, 160.0, 135.7, 135.5, 
129.1, 129.1, 128.5, 128.4, 127.5, 127.5, 116.8 (ddd, J = 1.47, 5.14, 20.54 Hz), 105.1 (dd, J = 
21.27, 28.61 Hz), 105.0 (dd, J = 21.27, 28.61 Hz), 101.6, 101.5, 59.9, 59.6, 54.0, 53.8, 14.0, 
13.6; (max/cm-1) 1676, 1628, 1604, 1434, 1379, 1366, 1329, 1311, 1301, 1231, 1175, 1139, 
1050, 1019, 855, 844, 802, 777, 732, 721, 692, 652, 580. See notes A, B. 
Compound 2d, white solid, 1.260 g (79.7% yield); 1H NMR (400 MHz, CDCl3) δ 12.83 
(d, J = 13.85 Hz, 0.66H), 11.46 (d, J = 13.60 Hz, 0.33H), 8.99 (d, J = 13.60 Hz, 0.66H), 8.85 
(d, J = 13.85 Hz, 0.33H), 7.74 (d, J = 2.27 Hz, 0.66H), 7.72 (d, J = 2.01 Hz, 0.33H), 7.44 - 7.51 
(m, 1H), 7.42 (dd, J = 7.81, 1.01 Hz, 0.33H), 7.36 (ddd, J = 9.82, 8.81, 6.29 Hz, 0.66H), 7.24 
- 7.31 (m, 1H), 7.20 - 7.24 (m, 0.66H), 7.16 - 7.20 (m, 0.33H), 6.92 (m, 1H), 6.86 (d, J = 2.01 
Hz, 0.66H), 6.84 (d, J = 2.27 Hz, 0.33H), 4.12 - 4.19 (m, 2H), 1.15 (t, J = 7.18 Hz, 2H), 1.04 
(t, J = 7.18 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 189.0, 186.3, 168.2, 166.5, 154.5 (ddd, J 
= 2.93, 9.54, 247.95 Hz), 153.4, 152.5, 151.0 (ddd, J = 12.47, 14.67, 254.56 Hz), 146.7 (ddd, 
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J = 3.67, 12.47, 245.75 Hz), 145.8, 145.7, 145.0, 144.8, 129.5, 129.4, 126.8 - 127.0 (m), 124.2, 
123.9, 123.8, 118.6, 118.0 - 118.2 (m), 118.0, 117.2 (ddd, J = 1.47, 5.13, 20.54 Hz), 112.4, 
111.5, 107.2, 105.2 (dd, J = 21.27, 28.61 Hz), 105.1 (dd, J = 21.27, 28.61 Hz), 104.8, 104.3, 
60.3, 60.2, 14.0, 13.7; (max/cm-1) 1701, 1624, 1596, 1567, 1506, 1448, 1428, 1307, 1251, 1207, 
1179, 1136, 1085, 1060, 1031, 1015, 976, 877, 812, 786, 729, 618, 599, 586, 566, 535, 519. 
See notes A, B. 
Compound 2e, yellow solid, 1.354 g (86.5% yield); 1H NMR (400 MHz, CDCl3) δ 
12.80 (d, J = 13.35 Hz, 0.66H), 11.31 (d, J = 13.60 Hz, 0.33H), 8.78 (d, J = 13.09 Hz, 0.66H), 
8.66 (d, J = 13.60 Hz, 0.33H), 7.75 (dd, J = 7.93, 0.63 Hz, 0.66H), 7.71 (dd, J = 7.93, 0.63 Hz, 
0.33H), 7.55 (dd, J = 5.29, 0.50 Hz, 0.66H), 7.53 (dd, J = 5.29, 0.50 Hz, 0.33H), 7.43 - 7.50 
(m, 2H), 7.28 - 7.43 (m, 2H), 6.88 - 6.97 (m, 1H), 4.13 - 4.21 (m, 2H), 1.16 (t, J = 7.18 Hz, 
2H), 1.05 (t, J = 7.18 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 189.1, 186.3, 168.3, 166.3, 
153.2, 152.4, 141.7, 141.6, 133.9, 133.8, 131.0, 126.7, 126.4, 125.6, 125.5, 124.9, 124.8, 121.7, 
121.1, 117.2 (ddd, J = 1.47, 5.14, 20.54 Hz), 112.6, 111.8, 105.2 (dd, J = 21.27, 28.61 Hz), 
105.2 (dd, J = 21.27, 28.61 Hz), 104.4, 60.4, 60.3, 14.0, 13.7; (max/cm-1) 1693, 1620, 1595, 
1507, 1435, 1383, 1324, 1293, 1248, 1186, 1139, 1100, 1020, 978, 893, 787, 761, 734 701, 
666, 593, 564. See notes A, B. 
Compound 2f, pale yellow solid, 491 mg (85.7% yield); 1H NMR (400 MHz, CDCl3) δ 
11.10 - 11.32 (m, 0.75H), 9.64 - 9.81 (m, 0.25H), 8.32 (d, J = 13.85 Hz, 0.75H), 8.28 (d, J = 
14.35 Hz, 0.25H), 7.68 - 7.72 (m, 1H), 7.60 - 7.64 (m, 1H), 7.33 (ddd, J = 10.07, 8.81, 6.29 
Hz, 0.25H), 7.16 - 7.30 (m, 3H), 6.82 - 6.91 (m, 2H), 4.86 - 4.92 (m, 2H), 4.07 (q, J = 7.05 Hz, 
1.5H), 4.00 (q, J = 7.05 Hz, 0.5H), 1.08 (t, J = 7.05 Hz, 2.25H), 0.94 (t, J = 7.05 Hz, 0.75H); 
13C NMR (101 MHz, CDCl3) δ 188.2, 186.1, 168.4, 166.7, 160.7, 160.2, 154.1 (ddd, J = 2.93, 
9.54, 247.22 Hz), 152.7, 146.6 (ddd, J = 3.67, 12.47, 245.75 Hz), 145.4, 127.9, 127.9, 127.3 - 
127.6 (m), 123.5, 123.5, 123.2, 121.9, 121.8, 119.6, 119.4, 117.6 (ddd, J = 1.47, 5.14, 20.54 
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Hz), 116.8 (ddd, J = 1.47, 5.14, 20.54 Hz), 106.9, 106.9, 105.0 (dd, J = 20.54, 28.61 Hz), 105.0 
(dd, J = 20.54, 28.61 Hz), 101.6, 101.5, 59.9, 59.6, 49.2, 49.0, 14.0, 13.6; (max/cm-1) 1690, 
1630, 1576, 1519, 1509, 1428, 1385, 1365, 1331, 1305, 1255, 1228, 1170, 1135, 1095, 1071, 
1028, 967, 879, 812, 783, 741, 658, 627, 584, 567, 510. See notes A, B. 
 Compound 2g, white solid, 348 mg (81.3% yield); 1H NMR (400 MHz, CDCl3) δ 11.19 
(br. s., 0.9H), 9.70 (br. s., 0.1H), 8.29 (d, J = 13.85 Hz, 0.9H), 8.23 (d, J = 14.35 Hz, 0.1H), 
7.82 - 7.88 (m, 1H), 7.48 - 7.53 (m, 1H), 7.39 - 7.45 (m, 2H), 7.31 (d, J = 6.80 Hz, 1H), 7.21 
(ddd, J = 10.07, 8.81, 6.17 Hz, 1H), 6.87 (ddd, J = 10.07, 9.06, 6.29 Hz, 1H), 4.83 - 4.88 (m, 
2H), 4.07 (q, J = 7.05 Hz, 1.8H), 4.01 (q, J = 7.05 Hz, 0.2H), 1.08 (t, J = 7.05 Hz, 2.7H), 0.94 
(t, J = 7.05 Hz, 0.3H); 13C NMR (101 MHz, CDCl3) δ 188.4, 168.4, 166.6, 160.7, 160.2, 140.5, 
138.2, 138.1, 129.6, 126.4, 126.4, 124.9, 124.8, 124.7, 124.6, 124.1, 124.1, 123.4, 123.4, 116.9 
(ddd, J = 1.47, 5.14, 20.54 Hz), 105.1 (dd, J = 21.27, 28.61 Hz), 101.9, 60.0, 59.7, 53.1, 52.9, 
14.0, 13.6; (max/cm-1) 1695, 1627, 1573, 1507, 1430, 1383, 1329, 1303, 1256, 1229, 1217, 
1171, 1134, 1091, 1070, 1032, 995, 846, 813, 782, 742, 704, 660, 587, 568, 552. See notes A, 
B. 
 General Procedure for Compounds 3a – g. Compound 2a (1 g, 3.13 mmol, 1 eq.) 
was dissolved in DCM (7 mL), then DBU (573 μL, 3.83 mmol, 1.2 eq.) and LiCl (270 mg, 6.38 
mmol, 2 eq.) were added and the reaction was stirred at 45 °C for 2.5 hours, then at room 
temperature for 15 hours. Upon completion, the mixture was extracted with DCM (2 x 20 mL) 
and washed with distilled water (15 mL) with the aqueous phase neutralised using a 1M 
solution of citric acid (3 mL). The combined organic phases were dried over magnesium 
sulphate, filtered and concentrated in vacuo. The crude product 3a was used in the successive 
reaction without further purification. Compound 3a, pale yellow solid, 1.022 g (>95% crude 
yield), 1H NMR (400 MHz, CDCl3) δ 8.55 (s, 1H, H3), 8.20 (dd, J = 10.45, 8.69 Hz, 1H, H1), 
7.72 (dd, J = 11.33, 6.29 Hz, 1H, H2), 4.37 (q, J = 7.05 Hz, 2H, H7), 3.41 - 3.48 (m, 1H, H4), 
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1.32 - 1.43 (m, 5H, H5+6+8), 1.12 - 1.19 (m, 2H, H5+6); 13C NMR (101 MHz, CDCl3) δ 172.6 
(d, J = 1.47 Hz), 165.2, 153.3 (dd, J = 256.03, 15.41 Hz), 148.8, 148.6 (dd, J = 250.89, 13.94 
Hz), 137.5 (dd, J = 9.54, 2.20 Hz), 125.6 (dd, J = 5.13, 2.20 Hz), 115.3 (dd, J = 19.07, 2.20 
Hz), 110.8, 105.5 (d, J = 22.74 Hz), 61.0, 34.8, 14.3, 8.2; (max/cm-1) 1723, 1617, 1602, 1490, 
1479, 1454, 1446, 1424, 1396, 1386, 1379, 1335, 1314, 1287, 1228, 1209, 1202, 1167, 1121, 
1094, 1054, 1033, 1018, 899, 855, 849, 826, 802, 781, 748, 729, 717, 619, 607, 595, 548, 540; 
LC-MS retention time 3.28 minutes (method A), purity = 100%, found 294.0 [M+H]+, 
calculated for C15H13F2NO3 294.27 [M+H]
+. 
 Compound 3b, pale yellow solid, 4.55 g (>95% crude yield), 1H NMR (400 MHz, 
CDCl3) δ 8.47 (s, 1H, H3), 8.27 (dd, J = 10.32, 8.81 Hz, 1H, H1), 7.27 (dd, J = 11.21, 6.17 Hz, 
1H, H2), 4.38 (q, J = 7.05 Hz, 2H, H6), 4.21 (q, J = 7.22 Hz, 2H, H4), 1.55 (t, J = 7.30 Hz, 3H, 
H5), 1.40 (t, J = 7.05 Hz, 3H, H7); 13C NMR (101 MHz, CDCl3) δ 172.6 (d, J = 2.20 Hz), 
165.3, 153.5 (dd, J = 256.02, 15.41 Hz), 148.7, 148.3 (dd, J = 251.62, 13.94 Hz), 135.5 (dd, J 
= 8.80, 2.20 Hz), 126.4 (dd, J = 5.13, 2.20 Hz), 115.7 (dd, J = 18.34, 2.20 Hz), 111.0, 104.6 
(d, J = 22.01 Hz), 61.0, 49.3, 14.3, 14.3; (max/cm-1) 1720, 1617, 1566, 1466, 1449, 1375, 1369, 
1311, 1288, 1228, 1217, 1209, 1173, 1157, 1137, 1094, 1071, 1049, 1016, 902, 863, 829, 814, 
802; LC-MS retention time 3.18 minutes (method A), purity = 100%, found 281.9 [M+H]+, 
calculated for C14H13F2NO3 282.26 [M+H]
+. 
 Compound 3c, pale yellow solid, 540 mg (57.2% crude yield); 1H NMR (400 MHz, 
CDCl3) δ 8.59 (s, 1H), 8.28 (dd, J = 10.45, 8.69 Hz, 1H), 7.38 - 7.41 (m, 2H), 7.33 - 7.43 (m, 
3H), 7.09 - 7.20 (m, 3H), 5.35 (s, 2H), 4.40 (q, J = 7.22 Hz, 2H), 1.41 (t, J = 7.18 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 172.7 (d, J = 1.47 Hz), 165.2, 153.3 (dd, J = 15.41, 256.03 Hz), 
149.9, 148.5 (dd, J = 13.94, 251.62 Hz), 136.1 (d, J = 11.00 Hz), 133.3, 129.6, 128.9, 126.4 
(dd, J = 2.20, 5.14 Hz), 126.0, 115.6 (dd, J = 2.20, 18.34 Hz), 111.1, 105.7 (d, J = 22.74 Hz), 
61.1, 57.9, 14.3; (max/cm-1) 1718, 1617, 1598, 1492, 1454, 1387, 1287, 1228, 1206, 1168, 
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1077, 922, 894, 825, 800, 731, 703, 620, 536; LC-MS retention time 3.62 minutes (method A), 
purity = 100%, found 344.1 [M+H]+, calculated for C19H15F2NO3 344.33 [M+H]
+. 
 Compound 3d, pale yellow solid, 846 mg (89.1% crude yield); 1H NMR (400 MHz, 
CDCl3) δ 8.56 (s, 1H), 8.33 (dd, J = 10.32, 8.56 Hz, 1H), 7.88 (dd, J = 7.81, 1.01 Hz, 1H), 7.66 
(d, J = 2.01 Hz, 1H), 7.49 (t, J = 7.68 Hz, 1H), 7.41 (dd, J = 7.68, 1.13 Hz, 1H), 6.98 (d, J = 
2.27 Hz, 1H), 6.68 (dd, J = 11.08, 6.29 Hz, 1H), 4.39 (q, J = 7.05 Hz, 2H), 1.39 (t, J = 7.05 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 172.9 (d, J = 2.20 Hz), 165.0, 153.4 (dd, J = 14.67, 256.02 
Hz), 149.4, 149.0, 148.7 (dd, J = 13.94, 251.62 Hz), 146.6, 137.2 (dd, J = 2.20, 9.54 Hz), 130.4, 
125.4 - 125.5 (m), 124.6, 124.2, 123.9, 122.9, 115.2 (dd, J = 2.20, 18.34 Hz), 111.8, 107.5, 
106.3 (d, J = 22.74 Hz), 61.2, 14.4; (max/cm-1) 1685, 1646, 1612, 1566, 1491, 1436, 1279, 
1211, 1168, 1116, 1085, 1048, 1009, 904, 855, 800, 738, 631, 604, 561; LC-MS retention time 
3.78 minutes (method A), purity = 100%, found 370.0 [M+H]+, calculated for C20H13F2NO4 
370.32 [M+H]+. 
 Compound 3e, pale yellow solid, 817 mg (85.8% crude yield); 1H NMR (400 MHz, 
CDCl3) δ 8.56 (s, 1H), 8.32 (dd, J = 10.32, 8.56 Hz, 1H), 8.09 (dd, J = 7.93, 0.88 Hz, 1H), 7.61 
- 7.66 (m, 1H), 7.54 (m, 2H), 7.47 (dd, J = 7.55, 0.76 Hz, 1H), 6.64 (dd, J = 10.83, 6.42 Hz, 
1H), 4.38 (q, J = 7.05 Hz, 2H), 1.38 (t, J = 7.18 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.9 
(d, J = 1.47 Hz), 164.8, 153.5 (dd, J = 14.67, 256.03 Hz), 148.8 (dd, J = 13.94, 251.62 Hz), 
148.7, 142.4, 137.4, 136.5 - 136.6 (m), 134.3, 128.1, 126.5, 125.9, 125.5 (dd, J = 2.20, 5.14 
Hz), 124.9, 123.4, 115.3 (dd, J = 2.20, 19.07 Hz), 112.0, 106.2 (d, J = 22.74 Hz), 61.2, 14.3; 
(max/cm-1) 1729, 1619, 1556, 1492, 1397, 1383, 1318, 1285, 1243, 1217, 1202, 1170, 1072, 
1029, 901, 851, 803, 727, 699, 618, 605; LC-MS retention time 3.88 minutes (method A), 
purity = 100%, found 385.9 [M+H]+, calculated for C20H13F2NO3S 386.38 [M+H]
+. 
 Compound 3f, pale yellow solid, 405 mg (94.3% crude yield); 1H NMR (400 MHz, 
CDCl3) δ 8.77 (s, 1H), 8.22 - 8.30 (m, 1H), 7.68 - 7.71 (m, 1H), 7.62 (d, J = 7.81 Hz, 1H), 7.38 
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(dd, J = 11.33, 6.04 Hz, 1H), 7.20 - 7.26 (m, 1H), 7.04 (d, J = 7.55 Hz, 1H), 6.82 - 6.86 (m, 
1H), 5.61 (s, 2H), 4.41 (q, J = 7.05 Hz, 2H), 1.42 (t, J = 7.05 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 172.8, 165.3, 153.3 (dd, J = 13.94, 256.02 Hz), 152.0, 150.2, 148.4 (dd, J = 13.94, 
251.62 Hz), 145.6, 136.1 (dd, J = 1.47, 9.54 Hz), 128.3, 126.3 (dd, J = 2.20, 5.14 Hz), 123.5, 
122.5, 122.3, 117.0, 115.6 (dd, J = 2.20, 18.34 Hz), 111.1, 107.1, 105.4 (d, J = 23.47 Hz), 61.1, 
53.1, 14.4; (max/cm-1) 1674, 1650, 1612, 1493, 1427, 1317, 1290, 1247, 1220, 1126, 1093, 
1031, 905, 874, 827, 802, 784, 750, 724, 711, 631, 606, 555, 525; LC-MS retention time 3.73 
minutes (method A), purity = 100%, found 383.9 [M+H]+, calculated for C21H15F2NO4 384.35 
[M+H]+. 
 Compound 3g, pale yellow solid, 290 mg (>95% crude yield); 1H NMR (400 MHz, 
CDCl3) δ 8.69 (s, 1H), 8.26 - 8.32 (m, 1H), 7.84 - 7.90 (m, 1H), 7.53 (d, J = 5.54 Hz, 1H), 7.47 
(m, 1H), 7.34 - 7.40 (m, 1H), 7.08 (dd, J = 11.08, 6.29 Hz, 1H), 6.96 - 7.02 (m, 1H), 5.54 (s, 
2H), 4.40 (q, J = 7.05 Hz, 2H), 1.41 (t, J = 7.18 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.8 
(d, J = 1.47 Hz), 165.1, 153.4 (dd, J = 15.41, 256.76 Hz), 150.2, 148.6 (dd, J = 13.94, 252.36 
Hz), 140.9, 136.7, 136.1 - 136.3 (m), 127.3, 126.6, 126.2 - 126.4 (m), 125.1, 124.9, 124.5, 
121.8, 115.7 (dd, J = 2.20, 18.34 Hz), 111.4, 105.3 (d, J = 22.74 Hz), 61.3, 57.0, 14.4; (max/cm-
1) 1674, 1647, 1613, 1477, 1395, 1316, 1290, 1223, 1172, 1085, 1051, 830, 802, 786, 680, 605, 
564; LC-MS retention time 3.85 minutes (method A), purity = 100%, found 400.1 [M+H]+, 
calculated for C21H15F2NO3S 400.41 [M+H]
+. 
 General Procedure for Compounds 4a, 4b. Compound 3a (700 mg, 2.39 mmol, 1 
eq.) was refluxed with concentrated HCl (3.5 mL) and concentrated AcOH (13 mL) for 2.5 
hours. The mixture was allowed to cool to room temperature and the resulting precipitate was 
filtered, washed with distilled water (3 mL) and dried. The crude product 4a was used in the 
successive reaction without further purification. Compound 4a, white solid, 573 mg (90.4% 
yield); 1H NMR (400 MHz, CF3CO2D) δ 9.43 (s, 1H, H3), 8.41 - 8.52 (m, 2H, H1+2), 4.07 - 
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4.18 (m, 1H, H4), 1.64 - 1.73 (m, 2H, H5+6), 1.41 - 1.49 (m, 2H, H5+6); 13C NMR (101 MHz, 
CF3CO2D) δ 174.8 (d, J = 4.01 Hz), 171.7, 160.1 (dd, J = 270.27, 15.26 Hz), 154.6 (dd, J = 
263.79, 14.50 Hz), 152.7, 142.7 (d, J = 10.87 Hz), 120.8 (dd, J = 8.20, 1.72 Hz), 115.8 (dd, J 
= 20.79, 3.24 Hz), 110.5 (d, J = 23.84 Hz), 106.9, 41.5, 10.0; (max/cm-1) 1719, 1614, 1556, 
1421, 1332, 1303, 1289, 1231, 1204, 1056, 1033, 1020, 891, 806, 778, 748, 719, 606; LC-MS 
retention time 3.37 minutes (method A), purity = 100%, found 265.9 [M+H]+, calculated for 
C13H9F2NO3 266.22 [M+H]
+. 
 Compound 4b, pale yellow solid, 2.964 g (73.2% yield); 1H NMR (400 MHz, 
CF3CO2D) δ 9.36 (s, 1H, H3), 8.39 (t, J = 8.43 Hz, 1H, H1), 7.99 (dd, J = 9.95, 6.17 Hz, 1H, 
H2), 4.79 (q, J = 7.13 Hz, 2H, H4), 1.66 (t, J = 7.05 Hz, 3H, H5); 13C NMR (101 MHz, 
CF3CO2D) δ 171.8 (d, J = 4.01 Hz), 169.1, 157.7 (dd, J = 270.27, 15.26 Hz), 151.9 (dd, J = 
263.79, 14.50 Hz), 149.4 (d, J = 1.15 Hz), 137.9 (d, J = 9.15 Hz), 118.8 (dd, J = 7.63, 1.33 Hz), 
113.4 (dd, J = 20.41, 3.43 Hz), 107.1 (d, J = 23.27 Hz), 104.7, 53.4, 12.9; (max/cm-1) 1719, 
1617, 1484, 1396, 1385, 1361, 1306, 1289, 1231, 1213, 1094, 1042, 948, 900, 874, 808; LC-
MS retention time 3.28 minutes (method A), purity = 100%, found 253.8 [M+H]+, calculated 
for C12H9F2NO3 254.2 [M+H]
+. 
 General Procedure for Compounds 4c – g. Crude compound 3c (450 mg, 1.31 mmol, 
1 eq.) was refluxed with LiOH (157 mg, 6.55 mmol, 5 eq.), water (3.28 mL) and dioxane (6 
mL) at 100 °C for 2 hours. The mixture was allowed to cool to room temperature. The resulting 
precipitate was acidified using 1M HCl, filtered, washed with water (3 mL) and dried in vacuo. 
The crude product 4c was used in the successive reaction without further purification. 
Compound 4c, white solid, 170 mg (41.2% yield); 1H NMR (400 MHz, CF3CO2D) δ 9.39 (s, 
1H), 8.45 (t, J = 8.39 Hz, 1H), 8.05 (dd, J = 10.27, 6.24 Hz, 1H), 7.38 - 7.48 (m, 3H), 7.18 - 
7.27 (m, 2H), 5.92 (s, 2H); (max/cm-1) 1718, 1615, 1502, 1465, 1387, 1363, 1287, 1223, 1168, 
974, 919, 837, 807, 773, 753, 731, 716, 692, 607, 526, 522; LC-MS retention time 3.70 minutes 
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(method A), purity = 100%, found 316.0 [M+H]+, calculated for C17H11F2NO3 316.28 [M+H]
+. 
See note C. 
Compound 4d, white solid, 625 mg (84.4% yield); 1H NMR (400 MHz, CF3CO2D) δ 
9.48 (s, 1H), 8.56 (t, J = 8.25 Hz, 1H), 8.07 (d, J = 7.79 Hz, 1H), 7.53 - 7.68 (m, 3H), 7.33 (dd, 
J = 9.90, 6.24 Hz, 1H), 7.04 (d, J = 2.02 Hz, 1H); 13C NMR (101 MHz, CF3CO2D) δ 175.7 (d, 
J = 3.82 Hz), 171.6, 160.4 (dd, J = 15.64, 271.03 Hz), 154.7 (dd, J = 14.31, 263.4 Hz), 153.8, 
150.2, 149.8, 142.5 (d, J = 10.11 Hz), 133.8, 128.7, 126.8, 124.6, 123.8, 120.8 (d, J = 8.39 Hz), 
115.5 - 115.7 (m), 111.2 (d, J = 23.84 Hz), 109.8, 107.7; (max/cm-1) 1718, 1610, 1492, 1456, 
1334, 1290, 1263, 1220, 1208, 1017, 897, 851, 806, 793, 736, 720, 598, 562; LC-MS retention 
time 3.78 minutes (method A), purity = 100%, found 342.0 [M+H]+, calculated for 
C18H9F2NO4 342.27 [M+H]
+. 
 Compound 4e, pale yellow solid, 513 mg (73.6% yield); 1H NMR (400 MHz, 
CF3CO2D) δ 9.51 (s, 1H), 8.58 (t, J = 8.21 Hz, 1H), 8.28 (d, J = 8.07 Hz, 1H), 7.77 (t, J = 7.84 
Hz, 1H), 7.58 - 7.67 (m, 3H), 7.31 (dd, J = 9.86, 6.28 Hz, 1H); 13C NMR (101 MHz, CF3CO2D) 
δ 175.6 (d, J = 4.20 Hz), 171.3, 161.7 (dd, J = 15.64, 271.23 Hz), 154.6 (dd, J = 14.11, 264.36 
Hz), 153.0, 145.6, 141.4 - 141.6 (m), 138.0, 134.8, 130.0, 128.1, 127.2, 124.5, 120.7 - 120.8 
(m), 115.5 (dd, J = 3.05, 20.60 Hz), 110.9, (d, J = 24.03 Hz), 107.7; (max/cm-1) 1612, 1491, 
1477, 1460, 1388, 1279, 1218, 1023, 895, 850, 807, 746, 730, 697, 663, 648, 620; LC-MS 
retention time 3.93 minutes (method A), purity = 100%, found 357.9 [M+H]+, calculated for 
C18H9F2NO3S 358.33.33 [M+H]
+. 
 Compound 4f, white solid, 176 mg (50.0% yield); 1H NMR (400 MHz, CF3CO2D) δ 
9.69 (s, 1H), 8.42 (t, J = 8.34 Hz, 1H), 8.27 (dd, J = 10.41, 6.10 Hz, 1H), 7.68 (d, J = 7.34 Hz, 
1H), 7.55 (d, J = 2.11 Hz, 1H), 7.25 - 7.39 (m, 2H), 6.78 (d, J = 2.11 Hz, 1H), 6.21 (s, 2H); 
(max/cm-1) 1615, 1492, 1431, 1387, 1360, 1286, 1217, 1179, 1124, 1050, 1033, 1020, 957, 
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919, 903, 873, 840, 807, 740, 700, 607, 526; retention time 3.83 minutes (method A), purity = 
100%, found 356.0 [M+H]+, calculated for C19H11F2NO4 356.30 [M+H]
+. See note C. 
 Compound 4g, white solid, 170 mg (68.0% yield); 1H NMR (400 MHz, CF3CO2D) δ 
9.43 (s, 1H), 8.45 (t, J = 8.39 Hz, 1H), 8.10 (dd, J = 10.27, 6.24 Hz, 1H), 7.93 (d, J = 8.07 Hz, 
1H), 7.38 - 7.49 (m, 3H), 7.24 (d, J = 7.43 Hz, 1H), 6.16 (s, 2H); 13C NMR (101 MHz, 
CF3CO2D) δ 174.9 (d, J = 4.20 Hz), 171.6, 160.0 (dd, J = 14.88, 270.84 Hz), 154.4 (dd, J = 
14.88, 264.36 Hz), 152.6, 144.2, 141.1 - 141.3 (m), 140.1, 128.4, 128.2, 127.6, 127.3, 126.8, 
126.0, 121.2 - 121.3 (m), 115.9 (dd, J = 3.81, 20.22 Hz), 110.1 (d, J = 23.27 Hz), 107.0, 62.9; 
(max/cm-1) 1617, 1340, 1289, 1213, 1049, 821, 788, 743, 687, 605; LC-MS retention time 3.93 
minutes (method A), purity = 100%, found 371.9 [M+H]+, calculated for C19H11F2NO3S 372.36 
[M+H]+. 
 General Procedure for Compounds 5a, 5b. A mixture of 4a (500 mg, 1.89 mmol, 1 
eq.), tert-butyl piperazine-1-carboxylate (1.06 g, 5.67 mmol, 3 eq.) and potassium carbonate 
(552 mg, 3.78 mmol, 2 eq.) was stirred in DMF (18 mL) at 140 °C for 15 hours. Upon 
completion, the mixture was extracted with DCM (2 x 15 mL) and washed with distilled water 
(10 mL) with the aqueous layer neutralised using a 1M citric acid solution (3 mL). Combined 
organic layers were dried over magnesium sulphate, filtered and concentrated in vacuo. The 
crude solid was recrystallised from DMF (5 mL) to yield Boc-protected ciprofloxacin. This 
compound (200 mg, 0.46 mmol, 1 eq.) was then dissolved in dry DCM (7 mL), the mixture 
cooled to 0 °C and TFA (710 μL, 9.27 mmol, 20 eq.) added, then allowed to warm to room 
temperature over 2 hours. Upon completion, the solution was concentrated in vacuo and 
washed with toluene (4 x 3 mL). The crude was washed with EtOAc (5 mL) and MeOH (5 mL) 
to give pure compound 5a, pale orange solid, 150 mg (34.5% yield over two steps); 1H NMR 
(400 MHz, CF3CO2D) δ 9.29 (s, 1H, H3), 8.24 (d, J = 12.34 Hz, 1H, H1), 7.90 (d, J = 6.80 Hz, 
1H, H2), 4.03 - 4.12 (m, 1H, H4), 3.90 - 3.99 (m, 4H, H8+9), 3.70 - 3.78 (m, 4H, H10+11), 
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1.60 - 1.68 (m, 2H, H5+6), 1.34 - 1.43 (m, 2H, H5+6); 13C NMR (101 MHz, CF3CO2D) δ 
173.2, 172.4, 157.6 (d, J = 258.64 Hz), 151.5, 150.5 (d, J = 10.87 Hz), 143.5, 117.9 (d, J = 
10.11 Hz), 114.2 (d, J = 25.18 Hz), 108.0, 105.7, 48.5 (d, J = 5.34 Hz), 46.8, 40.8, 9.9; (max/cm-
1) 1685, 1627, 1612, 1490, 1454, 1341, 1272, 1259, 1184, 1138, 1107, 1056, 1034, 941, 894, 
886, 829, 807, 793, 785, 749, 723, 708, 665, 637, 609; LC-MS retention time 2.48 minutes 
(method A), purity = 100%, found 332.0 [M+H]+, calculated for C17H18FN3O3 332.35 [M+H]
+. 
Compound 5b, pale brown solid, 44 mg (33.3% yield over two steps); 1H NMR (400 
MHz, CF3CO2D) δ 9.30 (s, 1H, H3), 8.29 (d, J = 12.09 Hz, 1H, H1), 7.48 (d, J = 6.55 Hz, 1H, 
H2), 4.85 (q, J = 7.22 Hz, 2H, H4), 3.91 - 3.99 (m, 4H, H7+8), 3.71 - 3.79 (m, 4H, H9+10), 
1.74 (t, J = 7.30 Hz, 3H, H5); 13C NMR (101 MHz, CF3CO2D) δ 170.3, 169.7, 154.9 (d, J = 
258.64 Hz), 148.2, 147.9 (d, J = 10.68 Hz), 138.8, 115.9 (d, J = 9.54 Hz), 111.7 (d, J = 27.47 
Hz), 104.6, 103.3, 52.6, 45.9 (d, J = 6.10 Hz), 44.2, 12.7; (max/cm-1) 1696, 1624, 1610, 1508, 
1474, 1453, 1421, 1399, 1382, 1366, 1310, 1265, 1202, 1125, 1104, 1088, 1053, 1033, 990, 
934, 916, 900, 828, 808, 797, 748, 720; LC-MS retention time 2.38 minutes (method A), purity 
= 85.5%, found 320.0 [M+H]+, calculated for C16H18FN3O3 320.33 [M+H]
+. 
 General Procedure for Compounds 5c – 5g. A mixture of compound 4c (150 mg, 
0.48 mmol, 1 eq.), piperazine (248 mg, 2.88 mmol, 6 eq.) and potassium carbonate (133 mg, 
0.96 mmol, 2 eq.) was stirred in DMF (2.5 mL) at 140 °C for 2 hours. Upon completion (as 
monitored by LC-MS), the mixture was extracted with DCM (2 x 15 mL) and washed with 
water (10 mL) with the aqueous layer neutralised using a 1M solution of citric acid (2 mL). 
The combined organic layers were dried over magnesium sulfate and concentrated in vacuo. 
The crude compound was recrystallised from DMF (500 µL) and the crude solid washed with 
EtOAc (5 mL) and MeOH (5 mL) to give pure compound 5c, white solid, 140 mg (76.5% 
yield); 1H NMR (400 MHz, CF3CO2D) δ 9.29 (s, 1H), 8.23 (d, J = 12.47 Hz, 1H), 7.41 - 7.47 
(m, 3H), 7.39 (d, J = 6.88 Hz, 1H), 7.18 - 7.28 (m, 2H), 5.91 (s, 2H), 3.69 - 3.86 (m, 4H), 3.52 
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- 3.69 (m, 4H); 13C NMR (101 MHz, CF3CO2D) δ 173.1, 172.2, 157.2 (d, J = 258.06 Hz), 
151.4, 149.9 (d, J = 10.87 Hz), 141.7, 133.0, 132.3, 132.1, 128.9, 118.3 (d, J = 9.92 Hz), 114.0 
(d, J = 26.13 Hz), 108.4, 105.5, 63.4, 48.1 (d, J = 5.53 Hz), 46.4; (max/cm-1) 1622, 1578, 1498, 
1447, 1390, 1337, 1278, 1262, 1215, 1199, 1179, 1137, 1032, 943, 825, 800, 778, 741, 696, 
625, 536, 516; LC-MS retention time 2.68 minutes (method A), purity = 100%, found 382.0 
[M+H]+, calculated for C21H20FN3O3 382.41 [M+H]
+. 
Compound 5d, white solid, 231 mg (32.2% yield); 1H NMR (400 MHz, CF3CO2D) δ 
9.35 (s, 1H), 8.41 (d, J = 12.29 Hz, 1H), 8.11 (dd, J = 7.79, 0.83 Hz, 1H), 7.71 (d, J = 2.20 Hz, 
1H), 7.66 (t, J = 7.84 Hz, 1H), 7.57 - 7.62 (m, 1H), 7.10 (d, J = 2.29 Hz, 1H), 6.83 (d, J = 6.88 
Hz, 1H), 3.55 - 3.77 (m, 8H); 13C NMR (101 MHz, CF3CO2D) δ 173.7, 172.0, 157.4 (d, J = 
258.45 Hz), 152.4, 150.4 (d, J = 10.49 Hz), 150.1, 149.4, 143.1, 133.5, 128.2, 126.6, 124.5, 
123.6, 117.7 (d, J = 10.87 Hz), 113.8 (d, J = 25.37 Hz), 109.7, 108.3, 106.2, 47.9 (d, J = 4.77 
Hz), 46.3; (max/cm-1) 1595, 1493, 1433, 1379, 1330, 1289, 1259, 1202, 1032, 909, 876, 800, 
736, 688, 624, 561, 552; LC-MS retention time 2.72 minutes (method A), purity = 100%, found 
408.0 [M+H]+, calculated for C22H18FN3O4 408.40 [M+H]
+. 
Compound 5e, pale yellow solid, 194 mg (36.4% yield); 1H NMR (400 MHz, 
CF3CO2D) δ 9.27 (s, 1H), 8.32 (d, J = 12.38 Hz, 1H), 8.22 (d, J = 8.07 Hz, 1H), 7.72 (t, J = 
7.84 Hz, 1H), 7.52 - 7.60 (m, 3H), 6.71 (d, J = 6.88 Hz, 1H), 3.44 - 3.65 (m, 8H); 13C NMR 
(101 MHz, CF3CO2D) δ 174.0, 172.2, 157.7 (d, J = 258.83 Hz), 152.1, 150.7 (d, J = 10.30 Hz), 
145.8, 142.4, 138.1, 135.3, 130.1, 130.0, 128.5, 127.5, 124.8, 117.8 - 118.0 (m), 114.2 (d, J = 
27.08 Hz), 108.6, 106.6, 48.1 (d, J = 4.77 Hz), 46.6; (max/cm-1) 1722, 1664, 1492, 1454, 1395, 
1352, 1326, 1285, 1251, 1100, 1042, 885, 802, 700, 661, 616, 563, 540; LC-MS retention time 
2.75 minutes (method A), purity = 100%, found 424.2 [M+H]+, calculated for C22H18FN3O3S 
424.46 [M+H]+. 
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Compound 5f, pale pink solid, 167 mg (94.4% yield); 1H NMR (400 MHz, CF3CO2D) 
δ 9.56 (s, 1H), 8.19 (d, J = 12.38 Hz, 1H), 7.63 - 7.74 (m, 1H), 7.49 - 7.63 (m, 2H), 7.29 (d, J 
= 4.22 Hz, 2H), 6.82 (br. s., 1H), 6.18 (s, 2H), 3.65 - 3.77 (m, 4H), 3.54 - 3.65 (m, 4H); 13C 
NMR (101 MHz, (CD3)2SO) δ 176.5, 166.3, 152.8 (d, J = 250.44 Hz), 152.0, 150.0, 146.6, 
145.4 (d, J = 10.30 Hz), 137.6, 127.9, 123.7, 123.5, 121.9, 119.0 (d, J = 7.06 Hz), 118.7, 111.3 
(d, J = 23.08 Hz), 107.3, 107.2, 106.0 (d, J = 1.91 Hz), 52.7, 50.4 (d, J = 4.77 Hz), 45.1; 
(max/cm-1) 1624, 1583, 1488, 1448, 1341, 1321, 1262, 1215, 1173, 1032, 1013, 940, 807, 793, 
747, 628; LC-MS retention time 2.78 minutes (method A), purity = 100%, found 422.0 
[M+H]+, calculated for C23H20FN3O4 422.43 [M+H]
+. 
Compound 5g, pale yellow solid, 41 mg (23.4% yield); 1H NMR (400 MHz, CF3CO2D) 
δ 9.45 (s, 1H), 8.20 (d, J = 12.29 Hz, 1H), 7.91 (d, J = 7.70 Hz, 1H), 7.44 - 7.52 (m, 2H), 7.41 
(t, J = 7.79 Hz, 1H), 7.32 (d, J = 6.60 Hz, 1H), 7.19 (d, J = 7.34 Hz, 1H), 6.13 (s, 2H), 3.53 - 
3.64 (m, 4H), 3.44 - 3.53 (m, 4H); (max/cm-1) 1621, 1583, 1488, 1448, 1338, 1279, 1266, 1204, 
1182, 1049, 1032, 940, 825, 793, 744, 689, 622, 554, 517; LC-MS retention time 5.53 minutes 
(method B), purity = 100%, found 437.9 [M+H]+, calculated for C23H20FN3O3S 438.49 
[M+H]+. See note C. 
 General Procedure for Compounds 6a – 6g. Compound 5a (150 mg, 0.45 mmol, 1 
eq.) was stirred in DCM (7 mL) for 5 minutes (method A), then 4M HCl in dioxane (2.26 mL, 
9.05 mmol, 20 eq.) was added dropwise and the mixture stirred for 1 hour. Upon completion, 
the mixture was washed with hexane (3 x 1 mL) and lyophilised overnight to give compound 
6a, pale brown solid; 1H NMR (400 MHz, (CD3)2SO) δ 15.13 (br. s., 1H, H7), 9.46 (br. s., 2H, 
H13), 8.67 (s, 1H, H3), 7.94 (d, J = 13.09 Hz, 1H, H1), 7.61 (d, J = 7.30 Hz, 1H, H2), 3.86 (br. 
s., 1H, H4), 3.53 - 3.60 (m, 4H, H8+9), 3.27 - 3.36 (m, 4H, H10+11), 1.28 - 1.37 (m, 2H, 
H5+6), 1.15 - 1.24 (m, 3H, H5+6+12); 13C NMR (101 MHz, (CD3)2SO) δ 176.4 (d, J = 2.93 
Hz), 165.9, 152.9 (d, J = 249.42 Hz), 148.2, 144.1 (d, J = 10.27 Hz), 139.1, 119.3 (d, J = 8.07 
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Hz), 111.2 (d, J = 23.47 Hz), 106.9 (d, J = 2.93 Hz), 106.8, 46.3 (d, J = 5.14 Hz), 42.5, 36.0, 
7.6; (max/cm-1) 1701, 1624, 1491, 1458, 1383, 1341, 1272, 1142, 1106, 1034, 941, 909, 889, 
853, 829, 804, 774, 749, 703, 665, 636, 619; LC-MS retention time 1.89 minutes (method A) 
and 4.70 minutes (method B), purity = 97.6% (found 332.1 [M+H]+) and 100% (found 332.0 
[M+H]+), respectively, calculated for C17H18FN3O3 332.35 [M+H]
+; HRMS observed 
332.1404 [M+H]+, theoretical value 332.1405 [M+H]+. 
Compound 6b, pale orange solid; 1H NMR (400 MHz, (CD3)2SO) δ 15.31 (br. s., 1H, 
H6), 9.37 (br. s., 2H, H12), 8.97 (s, 1H, H3), 7.96 (d, J = 13.09 Hz, 1H, H1), 7.26 (d, J = 7.30 
Hz, 1H, H2), 4.62 (q, J = 7.13 Hz, 2H, H4), 3.52 - 3.59 (m, 4H, H7+8), 3.25 - 3.33 (m, 4H, 
H9+10), 1.41 (t, J = 7.18 Hz, 3H, H5), 1.22 (d, J = 6.55 Hz, 1H, H11); 13C NMR (101 MHz, 
(CD3)2SO) δ 176.3 (d, J = 3.05 Hz), 166.3, 152.9 (d, J = 249.48 Hz), 148.9, 144.6 (d, J = 10.68 
Hz), 137.3, 120.1 (d, J = 7.63 Hz), 111.6 (d, J = 23.65 Hz), 107.3, 106.7 (d, J = 3.43 Hz), 49.3, 
46.6 (d, J = 4.58 Hz), 42.8, 14.6; (max/cm-1) 1701, 1696, 1626, 1507, 1454, 1345, 1340, 1332, 
1273, 1130, 1053, 1033, 933, 899, 859, 829, 804, 746, 665; LC-MS retention time 1.89 minutes 
(method A) and 3.29 minutes (method B), purity = 100% (found 320.1 [M+H]+) and 98.5% 
(found 320.1 [M+H]+), respectively, calculated for C16H18FN3O3 320.34 [M+H]
+; HRMS 
observed 320.1404 [M+H]+, theoretical value 320.1405 [M+H]+. 
Compound 6c, white solid; 1H NMR (400 MHz, (CD3)2SO) δ 15.14 (br. s., 1H), 9.57 
(br. s., 1H), 9.19 (s, 1H), 7.92 (d, J = 12.93 Hz, 1H), 7.06 - 7.48 (m, 6H), 5.90 (s, 2H), 3.41 (br. 
s., 4H), 3.22 (br. s., 4H); 13C NMR (101 MHz, (CD3)2SO) δ 176.4 (d, J = 1.53 Hz), 166.0, 
152.6 (d, J = 250.05 Hz), 149.6, 143.9 (d, J = 10.11 Hz), 137.5, 135.3, 129.0, 128.2, 127.0, 
120.1 (d, J = 7.44 Hz), 111.4 (d, J = 22.89 Hz), 107.3, 107.2 (d, J = 2.86 Hz), 56.5, 46.2 (d, J 
= 4.20 Hz), 42.3; (max/cm-1) 1718, 1627, 1507, 1453, 1383, 1367, 1268, 1254, 1207, 1059, 
1033, 1007, 960, 927, 903, 833, 802, 763, 739, 698, 535, 524; LC-MS retention time 2.17 
minutes (method A) and 4.24 minutes (method B), purity = 98.9% (found 382.1 [M+H]+) and 
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98.8% (found 382.1 [M+H]+), respectively, calculated for C21H20FN3O3 382.41 [M+H]
+; 
HRMS observed 382.1559 [M+H]+, theoretical value 382.1561 [M+H]+. 
Compound 6d, pale yellow solid; 1H NMR (400 MHz, (CD3)2SO) δ 14.91 (br. s., 1H), 
9.31 (br. s., 2H), 8.87 (s, 1H), 8.05 - 8.10 (m, 2H), 8.01 (dd, J = 7.81, 1.01 Hz, 1H), 7.74 (dd, 
J = 7.81, 1.01 Hz, 1H), 7.56 (t, J = 7.81 Hz, 1H), 7.22 (d, J = 2.27 Hz, 1H), 6.37 (d, J = 7.30 
Hz, 1H), 3.09 - 3.24 (m, 8H); 13C NMR (101 MHz, (CD3)2SO) δ 176.8 (d, J = 2.20 Hz), 165.4, 
153.0 (d, J = 250.89 Hz), 149.4, 148.3, 147.5, 144.6 (d, J = 11.00 Hz), 138.4, 129.9, 124.2, 
123.5, 123.3, 119.4 (d, J = 8.07 Hz), 111.5 (d, J = 23.48 Hz), 108.2, 107.7, 106.5 (d, J = 2.93 
Hz), 45.9 (d, J = 4.40 Hz), 42.3; (max/cm-1) 1724, 1627, 1505, 1451, 1380, 1331, 1271, 1201, 
1172, 1116, 1033, 1017, 908, 871, 804, 734, 625, 559, 549; LC-MS retention time 2.23 minutes 
(method A) and 5.17 minutes (method B), purity = 100% (both), found 408.1 [M+H]+ (both), 
calculated for C22H18FN3O4 408.40 [M+H]
+; HRMS observed 408.1352 [M+H]+, theoretical 
value 408.1354 [M+H]+. 
Compound 6e, pale orange solid; 1H NMR (400 MHz, (CD3)2SO) δ 9.47 (br. s., 2H), 
8.83 (s, 1H), 8.23 (d, J = 7.89 Hz, 1H), 8.07 (d, J = 12.93 Hz, 1H), 7.89 (d, J = 5.41 Hz, 1H), 
7.79 - 7.84 (m, 1H), 7.68 - 7.76 (m, 2H), 6.32 (d, J = 7.15 Hz, 1H), 3.04 - 3.26 (m, 8H); 13C 
NMR (101 MHz, (CD3)2SO) δ 176.8 (d, J = 2.48 Hz), 165.3, 153.0 (d, J = 250.05 Hz), 148.5, 
144.7 (d, J = 10.68 Hz), 142.1, 137.8, 136.3, 133.7, 128.8, 126.1, 126.1, 125.2, 123.9, 119.5 
(d, J = 7.63 Hz), 111.7 (d, J = 23.08 Hz), 108.4, 106.2 (d, J = 2.67 Hz), 45.9 (d, J = 4.77 Hz), 
42.2; (max/cm-1) 1722, 1666, 1627, 1499, 1439, 1396, 1354, 1268, 1181, 1032, 951, 901, 866, 
832, 799, 713, 684, 615, 555, 537; LC-MS retention time 2.33 minutes (method A) and 5.27 
minutes (method B), purity = 100% (both), found 424.1 [M+H]+ (both), calculated for 
C22H18FN3O3S 424.46 [M+H]
+; HRMS observed 424.1124 [M+H]+, theoretical value 
424.1126 [M+H]+. 
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 Compound 6f, pale orange solid; 1H NMR (400 MHz, (CD3)2SO) δ 15.11 (br. s., 1H), 
9.62 (br. s., 2H), 9.33 (s, 1H), 8.10 (d, J = 2.11 Hz, 1H), 7.90 (d, J = 13.11 Hz, 1H), 7.65 (d, J 
= 7.52 Hz, 1H), 7.38 (d, J = 7.24 Hz, 1H), 7.34 (d, J = 7.24 Hz, 1H), 7.28 (t, J = 7.57 Hz, 1H), 
7.00 (d, J = 2.20 Hz, 1H), 6.17 (s, 2H), 3.32 - 3.43 (m, 4H), 3.22 (br. s., 4H); 13C NMR (101 
MHz, (CD3)2SO) δ 176.4 (d, J = 2.48 Hz), 165.9, 152.6 (d, J = 249.67 Hz), 152.0, 150.0, 146.5, 
143.9 (d, J = 10.30 Hz), 137.4, 127.8, 123.9, 123.4, 121.9, 119.9 (d, J = 7.63 Hz), 118.5, 111.4 
(d, J = 22.89 Hz), 107.2, 107.1, 106.8 (d, J = 3.05 Hz), 52.5, 46.2 (d, J = 4.77 Hz), 42.2; 
(max/cm-1) 1712, 1624, 1546, 1496, 1448, 1387, 1268, 1209, 1179, 1032, 1015, 932, 801, 756, 
741, 557, 525, 510; LC-MS retention time 2.33 minutes (method A) and 4.70 minutes (method 
B), purity = 100% (both), found 422.1 [M+H]+ (both), calculated for C23H20FN3O4 422.43 
[M+H]+; HRMS observed 422.1507 [M+H]+, theoretical value 422.1511 [M+H]+. 
Compound 6g, red solid; 1H NMR (400 MHz, (CD3)2SO) δ 15.11 (br. s., 1H), 9.31 (s, 
1H), 9.24 (br. s., 2H), 7.95 (d, J = 13.11 Hz, 1H), 7.91 (d, J = 7.15 Hz, 1H), 7.78 (d, J = 5.41 
Hz, 1H), 7.53 (d, J = 5.50 Hz, 1H), 7.36 - 7.47 (m, 2H), 7.15 (d, J = 7.34 Hz, 1H), 6.16 (s, 2H), 
3.24 - 3.30 (m, 4H), 3.16 (br. s., 4H); 13C NMR (101 MHz, (CD3)2SO) δ 176.6 (d, J = 2.48 Hz), 
166.0, 152.7 (d, J = 250.05 Hz), 150.4, 143.8 (d, J = 10.30 Hz), 140.8, 137.8, 136.8, 129.2, 
127.7, 125.1, 124.6, 124.2, 123.7, 119.9 (d, J = 7.82 Hz), 111.6 (d, J = 23.08 Hz), 107.4, 106.9 
(d, J = 1.53 Hz), 56.7, 46.2 (d, J = 49.6 Hz), 42.4; (max/cm-1) 1707, 1617, 1507, 1395, 1300, 
1268, 1206, 1107, 1056, 1033, 940, 832, 802, 771, 725, 699, 620, 554, 516; LC-MS retention 
time 2.40 minutes (method A) and 4.81 minutes (method B), purity = 100% (both), found 438.1 
[M+H]+ (both), calculated for C23H20FN3O3S 438.49 [M+H]
+; HRMS observed 438.1278 
[M+H]+, theoretical value 438.1282 [M+H]+.  
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Notes 
A) Compounds 2a-g display complex and unusual splitting patterns and integrals in their 
associated NMR spectra. Since fluorine-decoupled carbon-13 NMR spectra could not be 
generated, the highly fluorinated nature of the aromatic rings in these compounds causes 
splitting of the signals of nearby carbons. Additionally, compounds 2a-g can all form two 
distinct structural isomers due to their common 3-aminoacrylate moiety. These pairs of 
isomers exist in equilibrium with an interconversion rate significantly less than the 
difference in frequency between the isomers (‘slow on the NMR timescale’) meaning that 
both isomers are fully resolved in 1H and 13C NMR spectra. 
B) Continuing from note A; the reduction in signal-to-noise ratio caused by the high degree 
of splitting of aromatic carbon signals, in combination with the twinning of each peak, 
precluded resolution of many of these peaks for some compounds. In some cases, several 
small baseline multiplets are visible in the correct chemical shift range and are most likely 
the aforementioned missing signals. 
C) Poor compound solubility in all deuterated solvents tested precluded analysis via carbon-
13 NMR. 
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